Ophthalmic Drugs Market

Ophthalmic Drugs Market Study by Anti-inflammatory Drugs, Anti-infective Drugs, Anti-glaucoma Drugs, Anti-allergy Drugs, and Anti-VEGF Drugs from 2023 to 2033

Analysis of Ophthalmic Drugs Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Ophthalmic Drugs Market Outlook (2023 to 2033)

Global demand for ophthalmic drugs is predicted to increase at a CAGR of 6.6% from 2023 to 2033. The global ophthalmic drugs market is valued at US$ 38 billion in 2023 and is thus anticipated to reach US$ 72 billion by 2033-end.

The use of ophthalmic drugs for retinal disorders is anticipated increase at a CAGR of 5% during the forecast period due to the increasing patient pool acquiring retinal problems, the presence of innovative pipeline drugs, and increased financing for the development of retinal disorder treatments.

Ophthalmic drugs are prescribed for the treatment of a variety of eye-related conditions, such as age-related macular degeneration (AMD), cytomegalovirus (CMV), diabetic macular edema, color blindness, and diabetic macular edema. The conjunctiva SAC might be injected with a liquid drop preparation, an ointment, or a lotion to administer the medication. The right dosage and strength of the medication are chosen, and it is administered to the eyes in the prescribed manner.

The issue of low bioavailability of medicinal substances after application to the eyeball is the primary driver of scientists' pervasive interest in these medication forms. These drugs may be administered through contact lenses, emulsions, ointments, aqueous gels, dendrimers, or nanosuspensions. Neomycin, antibiotics, bacitracin, and polymyxin are all used in the production of ophthalmic medications, which help to slow the spread of bacterial infections in the eyes.

There is an increase in incidences of eye-related diseases, particularly in developing countries, over the past several years. Visual impairment is a global health concern harming physical and mental health. The increasing patient pool of the visually impaired is anticipated to boost demand for healthcare spending on ophthalmic drugs.

The ophthalmic drugs market is expected to rise as a result of several major factors, including a growing elderly population, an increase in the prevalence of eye ailments, technological advancements, and rising healthcare spending awareness. Market expansion is being supported by the substantial financing and supportive measures being implemented by the governments of numerous countries to stimulate the creation of efficient ophthalmic medications with novel formulations and combinations.

Additional growth-promoting elements include substantial technological developments, such as the development of gene-drug therapy for the diagnosis and treatment of hereditary ophthalmic, neurovascular retinal, and retinoblastoma problems.

Furthermore, the easy accessibility of ophthalmic medications in the forms of eye solutions, drops, capsules, pills, gels, and ointments via several online and offline distribution channels is fostering market expansion. A favorable outlook for the ophthalmic drugs market is being created by other factors such as the rapid expansion of the pharmaceutical industry and an increase in R&D operations to develop affordable ocular drug delivery systems (ODDS).

Report Attributes


Ophthalmic Drugs Market Size (2023)

US$ 38 Billion

Projected Market Value (2033)

US$ 72 Billion

Global Market Growth Rate (2023 to 2033)

6.6% CAGR

Market Share of Anti-glaucoma Drugs


Key Companies Profiled

  • Alcon
  • Nicox S.A.
  • Novartis AG
  • Tapros
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Bayer AG

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Which Key Aspects are Shaping Ophthalmic Drug Demand across the World?

“Growing Usage of Contact Lenses and Rise in Geriatric Population”

Compared to the use of glasses, contact lens use has significantly increased in recent years. The use of contact lenses by individuals who experience dry eye conditions has led to a large rise in the need for ophthalmic medications.

Many people are suffering from age-related illnesses. The demand for pharmaceuticals used as preventative measures and for treating various ailments has increased recently, and this trend will continue during the projection period.

“Increase in Patients Suffering from Various Eye Disorders”

Demand for ophthalmic drugs is predicted to increase due to a rise in patients experiencing vision impairment. With the aid of various medications, it is possible to prevent these disorders, which will prove to be a significant opportunity for market expansion over the coming years. Surging diabetes incidence in the elderly population and the eye ailment known as diabetic retinopathy are the elements boosting sales of ophthalmic drugs.

“New Developments in Drug Delivery Techniques”

The ophthalmic drugs market is expected to increase as a result of rising research and development efforts to create and introduce novel ophthalmic medications, as well as several strategic initiatives by the major players. Ophthalmic drugs have a considerable competitive edge over their counterparts due to their multiyear drug delivery system. Implanted contact lenses and medicines are two other innovative medication delivery methods.

The development of gene therapies as an effective means of drug delivery is one of the major factors driving this industry. Gene therapy enables the modification of patient cells to produce particular therapeutic entities using viral or non-viral vectors in both in-vitro and in-vivo settings.

Gene therapy can be used to identify and treat retinoblastoma, neurovascular retinal abnormalities, and inherited ophthalmic illnesses such as retinitis pigmentosa. Over the projection period, there should be potential for market expansion as more research is needed to advance and widen the application of gene therapy across ophthalmic illnesses.

Growing awareness of advanced treatment options for a variety of eye disorders patients and medical professionals is driving the demand for novel ophthalmic drugs. Manufacturers are also concentrating on creating advanced drug delivery systems that can increase patient compliance rates and lessen negative effects related to conventional therapies.

What Obstacles Need to Be Tackled by Suppliers of Ophthalmic Drugs?

“Lack of Skilled Professionals and Adverse Effects of Ophthalmic Medications”

Market expansion is anticipated to be constrained by the loss of patent protection for popular medications used to treat eye illnesses and the absence of health insurance in developing countries. The high cost of product development is expected to restrain market growth over the coming years, according to pricing trends.

The market for ophthalmic drugs will be challenged by the shortage of skilled professionals and the adverse effects of ophthalmic medications may impede market revenue.

Ophthalmic drugs market size & growth forecast by Fact.MR

Which Region is Predicted to Lead Market Expansion Going Forward?

“Favorable Reimbursement Policies Driving Market Growth in North America”

North America accounts for 50% share of the global market owing to the rising prevalence of eye diseases. Growing initiatives by key market players to develop innovative drugs, favorable reimbursement policies, and growing awareness of early ophthalmic disease diagnosis are supporting market expansion in the region.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Country-wise Insights

Which Country is Asserting its Dominance in North America?

“Growing Awareness among People about Accessibility of Ophthalmic Drugs”

The market is predicted to be dominated by the United States due to the increase in the prevalence of blindness, vision impairment, and other eye-related illnesses. Market growth in the United States is attributed to the growing awareness among people about the accessibility of ophthalmic drugs, increased government investments in eye health, and the availability of qualified healthcare professionals.

What is Benefitting Providers of Ophthalmic Drugs in Germany?

“Increase in Drug Approvals in the Country”

The main reason fueling the expansion of the market in Germany is improved regulatory policies, which have strengthened consumer confidence in the pharmaceutical industry. Key companie's strategic moves toward the commercialization of a few medicines, the presence of a large patient pool, increased drug approvals, and a rise in the local supply of ophthalmic drugs are boosting market value in Germany.

What is Making Japan Stand Out in the Asia Pacific Market?

“Increasing Investments by Research Institutes for Innovations in Ophthalmic Drugs”

The growing elderly population, higher healthcare spending, improved healthcare infrastructure, and a rise in consumer disposable income levels are the factors supporting market expansion in Japan. Increasing investments by research institutes for innovations in ophthalmic drugs are driving market growth in Japan.

Category-wise Insights

Why are Anti-glaucoma Drugs Highly Preferred?

“Rising Pool of Glaucoma Patients Driving Sales of Anti-glaucoma Drugs”

Based on therapeutic class, the market is classified into anti-inflammatory drugs, anti-infective drugs, anti-glaucoma drugs, anti-allergy drugs, anti-VEGF drugs, and others. Anti-glaucoma drugs account for 60% share of the global market.

Abnormally high pressure in the eye is generally the cause of glaucoma, a group of eye illnesses that impair the optic nerve, which is necessary for clear vision. A class of pharmaceuticals called anti-glaucoma ophthalmic drugs is used to reduce the pressure inside the eye. These drugs may be useful in lowering the risk of glaucoma, a disorder that can impair eyesight.

Rising geriatric population, which is more prone to developing glaucoma, and the increasing prevalence of glaucoma are the elements driving the demand for anti-glaucoma drugs. Key businesses are putting more emphasis on creating innovative medicines and products to treat glaucoma patients. This is anticipated to result in more product releases, which will fuel market expansion.

Which Product Accounts for a Leading Market Share?

“Prescription Drugs More Preferred Due to High Efficacy in Treating Ocular Conditions”

Based on product, the market is divided into prescription drugs and OTC drugs. Prescription drugs hold 50% share of the global market owing to an increase in conditions such as AMD and diabetic retinopathy. Improved safety and efficacy are two variables driving the demand for prescription drugs.

Some prescription drugs have lubricating and moisturizing ingredients that temporarily increase tear production. Prescription drugs are chosen over over-the-counter ones because they are thought to be the most effective in treating ocular conditions.

Additionally, a rising success rate for recently introduced prescription-only medicines would support market expansion. Since these medications are intended to be applied to the eyes only, patients must have a prescription before receiving ophthalmic steroids.

Competitive Landscape

Top ophthalmic drug manufacturers are focusing on supply chain management, collaborations with other companies, and enhancing quality control to gain a competitive edge in the market. Leading companies are improving product standards of new ophthalmic drugs and innovating their development formula following safety regulations to lower the environmental impact.

Major players are investing heavily in extensive R&D initiatives to increase their market share. Product portfolio expansion and mergers and acquisitions are two important techniques used by key participants.

For instance :

  • Santen Pharmaceutical Co. and Singapore Eye Research Institute announced a strategic collaboration to develop new technologies for unmet medical needs in key ophthalmic drug domains. The company manufactures prescription drugs for corneal, retinal, and glaucoma diseases, which include Diquas, Tapros, Alesion, and Eylea. Novartis AG, another player, integrates new products into its existing pipeline of drugs. It specializes in innovative medicines and includes ophthalmic drug products such as Lucentis and Travoprost.
  • In 2022, Novartis acquired Kedalion Therapeutics and its ground-breaking ocular delivery system, which can improve the patient experience.

Key Segments of Ophthalmic Drugs Industry Research

  • By Therapeutic Class :

    • Anti-inflammatory Drugs
      • NSAIDs
      • Steroids
    • Anti-infective Drugs
      • Anti-fungal Drugs
      • Anti-bacterial Drugs
      • Others
    • Anti-glaucoma Drugs
      • Alpha Agonist
      • Beta Blockers
      • Prostaglandin Analogs
      • Combined Medication
      • Others
    • Anti-allergy Drugs
    • Anti-VEGF Drugs
    • Others
  • By Product :

    • Prescription Drugs
    • OTC Drugs
  • By Disease Indication :

    • Dry Eye
    • Glaucoma
    • Infection/Inflammation
    • Retinal Disorders
      • Wet AMD
      • Dry AMD
      • Diabetic Retinopathy
      • Others
    • Allergy
    • Uveitis
    • Others
  • By Distribution Channel :

    • Hospital Pharmacies
    • Online Pharmacies
    • Independent Pharmacies & Drug Stores
  • By Region :

    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa

- FAQs -

What is the value of the ophthalmic drugs market in 2023?

The global ophthalmic drugs market is valued at US$ 38 billion in 2023.

Which is the dominant regional market for ophthalmic drugs?

North America accounts for 50% share of the global market.

What is boosting the sales of ophthalmic drugs?

Increasing prevalence of eye diseases and growing geriatric population are driving market growth.

How big will the market for ophthalmic drugs be by 2033?

By 2033-end, the ophthalmic drugs market is expected to reach US$ 72 billion.

At what rate will ophthalmic drug demand evolve over the next ten years?

Worldwide consumption of ophthalmic drugs is estimated to rise at a CAGR of 6.6% through 2033.

Ophthalmic Drugs Market

Schedule a Call